home / stock / hcm / hcm news

HCM News and Press, HUTCHMED (China) Limited From 07/13/23

Stock Information
Company Name: HUTCHMED (China) Limited
Stock Symbol: HCM
Market: NASDAQ
Website: hutch-med.com
Menu
HCM HCM Quote HCM Short HCM News HCM Articles HCM Message Board
Get HCM Alerts

News, Short Squeeze, Breakout and More Instantly...
HCM - HUTCHMED Announces Changes to Board of Directors and Technical Committee 

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that with effect from July 13, 2023: (i)   ...
HCM - HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a Phase I study in China of HMPL-415, an investigational novel selectiv...

HCM - HUTCHMED to Announce 2023 Half-Year Financial Results

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2023 on Monday, July 31, 2023 at 7:00 am Eastern Da...

HCM - Earnings week ahead: Nike, Micron Technology, BlackBerry, Walgreens Boots Alliance and more

2023-06-23 15:22:26 ET As the end of the second quarter draws near, a range of notable companies are set to release their earnings reports next week. Leading the pack is Nike ( NYSE: NKE ), the footwear and sports apparel giant. Elsewhere, chip makers Micron Technology ( NASDA...
HCM - Dice, iCAD top healthcare gainers; Surgalign, Gracell among losers

2023-06-20 10:07:39 ET Gainers: DICE Therapeutics ( DICE ) +38% . iCAD ( ICAD ) +17% . Nuwellis ( NUWE ) +14% . Valneva ( VALN ) +14% . Cano Health ( CANO ) +13% . Losers: Surgalign ( SRGA ) -72% . Gracel...

HCM - HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 ...

HCM - Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

— Application Includes Data from Phase III FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive Care (“BSC”) vs. Placebo plus BSC for Adult Patients with Previously Treated Metastatic Colorectal Cancer &#...
HCM - HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data related to two novel investigational hematological maligna...

HCM - Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO-2 and FRESCO clinical trials — OSAKA, Japan and CAMBRIDGE, Mass. and HONG KONG and SHANGHAI, China and FLORHAM ...

HCM - HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data related to HUTCHMED’s novel investigational cancer t...
Previous 10 Next 10